Skip to search formSkip to main contentSkip to account menu

CP-461

Known as: CP 461, CP461, CP461 cpd 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2004
2004
Select Cyclic Nucleotide Phosphodiesterase Inhibitors in Colon Tumor Chemoprevention and Chemotherapy
Exisulind, and later generation drugs including CP461, are members of a group of new anticancer compounds known as Selective… 
2004
2004
Gateways to clinical trials.
Gateways to Clinical Trials is a guide to the most recent clinical trials in current literature and congresses. The data in the… 
Review
2004
Review
2004
Gateways to clinical trials.
Gateways to Clinical Trials is a guide to the most recent clinical trials in current literature and congresses. The data in the… 
2003
2003
Gateways to clinical trials.
Gateways to Clinical Trials is a guide to the most recent clinical trials in current literature and congresses. The data in the… 
2002
2002
CP248, a derivative of exisulind, causes growth inhibition, mitotic arrest, and abnormalities in microtubule polymerization in glioma cells.
Exisulind (sulindac sulfone) and two potent derivatives, CP248 and CP461, have been shown previously to cause growth inhibition… 
2002
2002
Phase I and pharmacokinetic trial of the proapoptotic sulindac analog CP-461 in patients with advanced cancer.
CP-461 is a member of a class of novel proapoptotic drugs that specifically inhibit cyclic GMP phosphodiesterases but not… 
2002
2002
CP 248 , a Derivative of Exisulind , Causes Growth Inhibition , Mitotic Arrest , and Abnormalities in Microtubule Polymerization in Glioma Cells 1
Exisulind (sulindac sulfone) and two potent derivatives, CP248 and CP461, have been shown previously to cause growth inhibition… 
2002
2002
Phase I and Pharmacokinetic Trial of the Proapoptotic Sulindac Analog CP-461 in Patients with Advanced Cancer 1
CP-461 is a member of a class of novel proapoptotic drugs that specifically inhibit cyclic GMP phosphodiesterases but not… 
2002
2002
CP 461 promising in chronic lymphocytic leukaemia, renal carcinoma and hormone-resistant prostate cancer
  • 2002
  • Corpus ID: 195143402
2001
2001
Exisulind and CP461 inhibit cell growth, induce apoptosis, and have synergy with herceptin and taxotere in breast cancer cells
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)